Gilead's anti-viral remdesivir gets FDA emergency use authorisation for treatment of COVID-19
May 02, 2020
California [USA], May 2 : US-based biopharmaceutical major Gilead Sciences said that the US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for investigational anti-viral remdesivir to treat COVID-19.